{"id":"NCT00594958","sponsor":"Valneva Austria GmbH","briefTitle":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51","officialTitle":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-04","completion":"2007-09","firstPosted":"2008-01-16","resultsPosted":"2014-01-23","lastUpdate":"2024-03-21"},"enrollment":639,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]}],"arms":[{"label":"IC51 Group A","type":"ACTIVE_COMPARATOR"},{"label":"IC51 Group B","type":"ACTIVE_COMPARATOR"},{"label":"IC51 Group C","type":"ACTIVE_COMPARATOR"}],"summary":"The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.","primaryOutcome":{"measure":"GMT for Anti-JEV Neutralizing Antibody","timeFrame":"day 56","effectByArm":[{"arm":"IC51 Group A","deltaMin":160.71,"sd":null},{"arm":"IC51 Group B","deltaMin":272.24,"sd":null},{"arm":"IC51 Group C","deltaMin":127.56,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":212},"commonTop":["Headache","Nasopharyngitis","Influenza Like Ilness","Fatigue","Myalgia"]}}